1-20 of 22
Jens Huober
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials

Paul Jank, Thomas Karn, Marion van Mackelenbergh, Judith Lindner, Denise Treue, Jens Huober, Knut Engels, Christine Solbach, Kurt Diebold, Frederik Marmé, Volkmar Müller, Andreas Schneeweiss, Hans-Peter Sinn, Tanja Fehm, Christian Schem, Elmar Stickeler, Peter Fasching, Jan Budczies, Bärbel Felder, Valentina Nekljudova, Johannes Holtschmidt, Michael Untch, Carsten Denkert, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3868–3880.
https://doi.org/10.1158/1078-0432.CCR-24-0459
Published: 03 September 2024
View article titled, An Analysis of <em>PIK3CA</em> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Open the PDF for An Analysis of <em>PIK3CA</em> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Hans Wildiers, Anne Armstrong, Eveline Cuypere, Florence Dalenc, Luc Dirix, Steve Chan, Frederik Marme, Carolina P. Schröder, Jens Huober, Francois P. Duhoux, Peter Vuylsteke, Agnes Jager, Etienne Brain, Sherko Kuemmel, Zsuzsanna Pápai, Catharina Willemien Menke-van der Houven van Oordt, Luca Perjesi, Christian Mueller, Chrystelle Brignone, Frederic Triebel
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (3): 532–541.
https://doi.org/10.1158/1078-0432.CCR-23-1173
Published: 01 February 2024
View article titled, Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR<sup>+</sup> Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
Open the PDF for Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR<sup>+</sup> Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial in another window
Includes: Supplementary data
Journal Articles

RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial

Theresa Link, Jens-Uwe Blohmer, Wolfgang D. Schmitt, Jan Dominik Kuhlmann, Marianne Just, Michael Untch, Oliver Stotzer, Peter A. Fasching, Marc Thill, Mattea Reinisch, Andreas Schneeweiss, Pauline Wimberger, Sabine Seiler, Jens Huober, Christian Jackisch, Kerstin Rhiem, Claus Hanusch, Bruno V. Sinn, Valentina Nekljudova, Sibylle Loibl, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4606–4612.
https://doi.org/10.1158/1078-0432.CCR-23-1801
Published: 14 November 2023
View article titled, RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial
Open the PDF for RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial in another window
Includes: Supplementary data
Journal Articles

Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis

Sara Pizzamiglio, Chiara Maura Ciniselli, Tiziana Triulzi, Chiara Gargiuli, Loris De Cecco, Evandro de Azambuja, Debora Fumagalli, Christos Sotiriou, Nadia Harbeck, Miguel Izquierdo, Paolo Nuciforo, Jens Huober, Vera Cappelletti, Saverio Cinieri, Martine Piccart, Maria Grazia Daidone, Giancarlo Pruneri, Mario Paolo Colombo, Elda Tagliabue, Paolo Verderio, Serena Di Cosimo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6307–6313.
https://doi.org/10.1158/1078-0432.CCR-21-1600
Published: 01 December 2021
View article titled, Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Open the PDF for Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis in another window
Includes: Supplementary data
Journal Articles

Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

Ioannis A. Vathiotis, Myrto K. Moutafi, Prajan Divakar, Thazin Nwe Aung, Tao Qing, Aileen Fernandez, Vesal Yaghoobi, Sarra El-Abed, Yingbo Wang, Sebastien Guillaume, Paolo Nuciforo, Jens Huober, Serena Di Cosimo, Sung-Bae Kim, Nadia Harbeck, Henry Gomez, Saba Shafi, Konstantinos N. Syrigos, George Fountzilas, Christos Sotiriou, Lajos Pusztai, Sarah Warren, David L. Rimm
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6156–6163.
https://doi.org/10.1158/1078-0432.CCR-21-2103
Published: 15 November 2021
View article titled, Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer
Open the PDF for Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

Komal Jhaveri, Dejan Juric, Yoon-Sim Yap, Sara Cresta, Rachel M. Layman, Francois P. Duhoux, Catherine Terret, Shunji Takahashi, Jens Huober, Nicole Kundamal, Qing Sheng, Alejandro Balbin, Yan Ji, Wei He, Adam Crystal, Serena De Vita, Giuseppe Curigliano
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5760–5770.
https://doi.org/10.1158/1078-0432.CCR-21-1095
Published: 01 November 2021
View article titled, A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Open the PDF for A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer in another window
Journal Articles

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial

David Venet, Mattia Rediti, Marion Maetens, Debora Fumagalli, David N. Brown, Samira Majjaj, Roberto Salgado, Lajos Pusztai, Nadia Harbeck, Sarra El-Abed, Yingbo Wang, Cristina Saura, Henry Gomez, Vladimir Fedorovich Semiglazov, Evandro de Azambuja, Jens Huober, Paolo Nuciforo, Serena Di Cosimo, Martine Piccart, Sherene Loi, Françoise Rothé, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5607–5618.
https://doi.org/10.1158/1078-0432.CCR-21-1317
Published: 15 October 2021
View article titled, Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
Open the PDF for Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial in another window
Includes: Supplementary data
Journal Articles

A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

Thomas Karn, Tobias Meissner, Karsten E. Weber, Christine Solbach, Carsten Denkert, Knut Engels, Peter A. Fasching, Bruno V. Sinn, Iris Schrader, Jan Budczies, Frederik Marmé, Volkmar Müller, Uwe Holtrich, Bernd Gerber, Christian Schem, Brandon M. Young, Claus Hanusch, Elmar Stickeler, Jens Huober, Marion van Mackelenbergh, Brian Leyland-Jones, Tanja Fehm, Valentina Nekljudova, Michael Untch, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1896–1904.
https://doi.org/10.1158/1078-0432.CCR-19-1954
Published: 15 April 2020
View article titled, A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Open the PDF for A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial in another window
Includes: Supplementary data
Journal Articles

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial

Serena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, Paola Tiberio, Marilena V. Iorio, Florentine Hilbers, Evandro de Azambuja, Lorena de la Peña, Miguel Izquierdo, Jens Huober, José Baselga, Martine Piccart, Filippo G. de Braud, Giovanni Apolone, Paolo Verderio, Maria Grazia Daidone
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (13): 3887–3895.
https://doi.org/10.1158/1078-0432.CCR-18-2507
Published: 01 July 2019
View article titled, Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Open the PDF for Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

Françoise Rothé, Maria Joao Silva, David Venet, Christine Campbell, Ian Bradburry, Ghizlane Rouas, Evandro de Azambuja, Marion Maetens, Debora Fumagalli, Vanessa Rodrik-Outmezguine, Serena Di Cosimo, Daniela Rosa, Stephen Chia, Andrew Wardley, Takayuki Ueno, Wolfgang Janni, Jens Huober, Jose Baselga, Martine Piccart, Sherene Loi, Christos Sotiriou, Sarah-Jane Dawson, Michail Ignatiadis
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (12): 3581–3588.
https://doi.org/10.1158/1078-0432.CCR-18-2521
Published: 14 June 2019
View article titled, Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Open the PDF for Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial in another window
Includes: Supplementary data
Journal Articles

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

Ariella B. Hanker, Joan T. Garrett, Mónica Valeria Estrada, Preston D. Moore, Paula González Ericsson, James P. Koch, Emma Langley, Sharat Singh, Phillip S. Kim, Garrett M. Frampton, Eric Sanford, Philip Owens, Jennifer Becker, M. Reid Groseclose, Stephen Castellino, Heikki Joensuu, Jens Huober, Jan C. Brase, Samira Majjaj, Sylvain Brohée, David Venet, David Brown, José Baselga, Martine Piccart, Christos Sotiriou, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1434.
https://doi.org/10.1158/1078-0432.CCR-18-4267
Published: 15 February 2019
View article titled, Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Open the PDF for Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 in another window
Journal Articles

Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor

Sibylle Loibl, Karsten Weber, Jens Huober, Kristin Krappmann, Frederik Marmé, Christian Schem, Knut Engels, Berit Maria Pfitzner, Sherko Kümmel, Jenny Furlanetto, Arndt Hartmann, Silvia Darb-Esfahani, Volkmar Müller, Annette Staebler, Gunter von Minckwitz, Ralf Kronenwett, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (14): 3358–3365.
https://doi.org/10.1158/1078-0432.CCR-17-2947
Published: 15 July 2018
View article titled, Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Open the PDF for Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor in another window
Includes: Supplementary data
Journal Articles

Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial

Sabine Riethdorf, Volkmar Müller, Sibylle Loibl, Valentina Nekljudova, Karsten Weber, Jens Huober, Tanja Fehm, Iris Schrader, Jörn Hilfrich, Frank Holms, Hans Tesch, Christian Schem, Gunter von Minckwitz, Michael Untch, Klaus Pantel
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5384–5393.
https://doi.org/10.1158/1078-0432.CCR-17-0255
Published: 14 September 2017
View article titled, Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Open the PDF for Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial in another window
Includes: Supplementary data
Journal Articles

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

Ariella B. Hanker, Joan T. Garrett, Mónica Valeria Estrada, Preston D. Moore, Paula González Ericsson, James P. Koch, Emma Langley, Sharat Singh, Phillip S. Kim, Garrett M. Frampton, Eric Sanford, Philip Owens, Jennifer Becker, M. Reid Groseclose, Stephen Castellino, Heikki Joensuu, Jens Huober, Jan C. Brase, Samira Majjaj, Sylvain Brohée, David Venet, David Brown, José Baselga, Martine Piccart, Christos Sotiriou, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4323–4334.
https://doi.org/10.1158/1078-0432.CCR-16-2287
Published: 01 August 2017
View article titled, HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Open the PDF for HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 in another window
Includes: Supplementary data
Journal Articles

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

José Baselga, Gail D. Lewis Phillips, Sunil Verma, Jungsil Ro, Jens Huober, Alice E. Guardino, Meghna K. Samant, Steve Olsen, Sanne L. de Haas, Mark D. Pegram
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (15): 3755–3763.
https://doi.org/10.1158/1078-0432.CCR-15-2499
Published: 31 July 2016
View article titled, Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Open the PDF for Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer

Sibylle Loibl, Silvia Darb-Esfahani, Jens Huober, Alexander Klimowicz, Jenny Furlanetto, Bianca Lederer, Arndt Hartmann, Holger Eidtmann, Berit Pfitzner, Peter A. Fasching, Katharina Tiemann, Christian Jackisch, Keyur Mehta, Gunter von Minckwitz, Michael Untch, Carsten Denkert
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (11): 2675–2683.
https://doi.org/10.1158/1078-0432.CCR-15-0965
Published: 31 May 2016
View article titled, Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
Open the PDF for Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study

Frederick Klauschen, Stephan Wienert, Wolfgang D. Schmitt, Sibylle Loibl, Bernd Gerber, Jens-Uwe Blohmer, Jens Huober, Thomas Rüdiger, Erhard Erbstößer, Keyur Mehta, Bianca Lederer, Manfred Dietel, Carsten Denkert, Gunter von Minckwitz
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (16): 3651–3657.
https://doi.org/10.1158/1078-0432.CCR-14-1283
Published: 13 August 2015
View article titled, Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study
Open the PDF for Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study in another window
Includes: Supplementary data
Journal Articles

Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70)

Claus Hanusch, Andreas Schneeweiss, Sibylle Loibl, Michael Untch, Stefan Paepke, Sherko Kümmel, Christian Jackisch, Jens Huober, Jörn Hilfrich, Bernd Gerber, Holger Eidtmann, Carsten Denkert, Serban Costa, Jens Uwe Blohmer, Knut Engels, Nicole Burchardi, Gunter von Minckwitz
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (13): 2924–2931.
https://doi.org/10.1158/1078-0432.CCR-14-2774
Published: 30 June 2015
View article titled, Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70)
Open the PDF for Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70) in another window
Journal Articles

Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

Gunter von Minckwitz, Wolfgang D. Schmitt, Sibylle Loibl, Berit M. Müller, Jens U. Blohmer, Bruno V. Sinn, Holger Eidtmann, Wolfgang Eiermann, Bernd Gerber, Hans Tesch, Jörn Hilfrich, Jens Huober, Tanja Fehm, Jana Barinoff, Thomas Rüdiger, Erhard Erbstoesser, Peter A. Fasching, Thomas Karn, Volkmar Müller, Christian Jackisch, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (16): 4521–4531.
https://doi.org/10.1158/1078-0432.CCR-12-3628
Published: 13 August 2013
View article titled, Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer
Open the PDF for Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial

Sabine Riethdorf, Volkmar Müller, Liling Zhang, Thomas Rau, Sibylle Loibl, Martina Komor, Marc Roller, Jens Huober, Tanja Fehm, Iris Schrader, Jörn Hilfrich, Frank Holms, Hans Tesch, Holger Eidtmann, Michael Untch, Gunter von Minckwitz, Klaus Pantel
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (9): 2634–2645.
https://doi.org/10.1158/1078-0432.CCR-09-2042
Published: 28 April 2010
View article titled, Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial
Open the PDF for Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial in another window
Includes: Supplementary data